Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Neoadjuvant ipilimumab plus nivolumab in synchronous clinical stage III melanoma
Judith M. Versluis, Irene L. M. Reijers, Elisa A. Rozeman, et al.
European Journal of Cancer (2021) Vol. 148, pp. 51-57
Open Access | Times Cited: 19

Showing 19 citing articles:

Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial
Irene L. M. Reijers, Alexander M. Menzies, Alexander C.J. van Akkooi, et al.
Nature Medicine (2022) Vol. 28, Iss. 6, pp. 1178-1188
Open Access | Times Cited: 226
Increasing cure rates of solid tumors by immune checkpoint inhibitors
Weijie Ma, Ruobing Xue, Zheng Zhu, et al.
Experimental Hematology and Oncology (2023) Vol. 12, Iss. 1
Open Access | Times Cited: 65
Influence of microbiota-associated metabolic reprogramming on clinical outcome in patients with melanoma from the randomized adjuvant dendritic cell-based MIND-DC trial
Carolina Alves Costa Silva, Gianmarco Piccinno, Déborah Suissa, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 12
Surgical Management of Melanoma: Advances and Updates
Juan A. Santamaria‐Barria, Joshua M.V. Mammen
Current Oncology Reports (2022) Vol. 24, Iss. 11, pp. 1425-1432
Closed Access | Times Cited: 19
Pathological Response and Immune Biomarker Assessment in Non-Small-Cell Lung Carcinoma Receiving Neoadjuvant Immune Checkpoint Inhibitors
Frank Rojas, Edwin R. Parra, Ignacio I. Wistuba, et al.
Cancers (2022) Vol. 14, Iss. 11, pp. 2775-2775
Open Access | Times Cited: 8
Neoadjuvant Therapy in Melanoma: Where Are We Now?
Mariam Saad, Ahmad A. Tarhini
Current Oncology Reports (2023) Vol. 25, Iss. 4, pp. 325-339
Closed Access | Times Cited: 4
Neoadjuvant ipilimumab plus nivolumab in locally advanced melanoma: A real-world single-centre retrospective study
Patrick Schummer, Valerie Glutsch, Lukas Haug, et al.
EJC Skin Cancer (2023) Vol. 1, pp. 100003-100003
Open Access | Times Cited: 4
Treatment of Stage III Resectable Melanoma—Adjuvant and Neoadjuvant Approaches
Ahmad A. Tarhini, Ella Castellano, Islam Eljilany
The Cancer Journal (2024) Vol. 30, Iss. 2, pp. 54-70
Closed Access | Times Cited: 1
Treatment strategies with electrochemotherapy for limb in-transit melanoma: real-world outcomes from a European, retrospective, cohort study
L Campana, Francesca Tauceri, Joana Bártolo, et al.
European Journal of Surgical Oncology (2024), pp. 108740-108740
Closed Access | Times Cited: 1
Clinical updates in neoadjuvant immunotherapy for melanoma before surgery
Mariam Saad, Ella Castellano, Ahmad A. Tarhini
Expert Review of Clinical Immunology (2023) Vol. 20, Iss. 8, pp. 927-943
Closed Access | Times Cited: 3
Neoadjuvant Immunotherapy Strategies in HPV-Related Head-and-Neck Cancer
Shin Saito, Hirofumi Shibata, Douglas R. Adkins, et al.
Current Otorhinolaryngology Reports (2022) Vol. 10, Iss. 1, pp. 108-115
Open Access | Times Cited: 5
Nidogen-2 (NID2) is a Key Factor in Collagen Causing Poor Response to Immunotherapy in Melanoma
Yan Sha, An-qi Mao, Yuan-jie Liu, et al.
Pharmacogenomics and Personalized Medicine (2023) Vol. Volume 16, pp. 153-172
Open Access | Times Cited: 1
Neoadjuvante Therapie des Melanoms
Lena Fuchs, Anja Gesierich, Patrick Schummer, et al.
best practice onkologie (2024)
Closed Access
Neoadjuvante Therapie des Melanoms
Lena Fuchs, Anja Gesierich, Patrick Schummer, et al.
Deleted Journal (2024) Vol. 30, Iss. 5, pp. 433-442
Closed Access
Current knowledge about immunotherapy resistance for melanoma and potential predictive and prognostic biomarkers
Lanni Song, Yixin Yang, Xuechen Tian
Cancer Drug Resistance (2024)
Open Access
Reflectance confocal microscopy – a non‐invasive tool for monitoring systemic treatment response in stage III unresectable primary scalp melanoma
Genevieve Ho, Rodrigo Schwartz, Amanda Pereira, et al.
Journal of the European Academy of Dermatology and Venereology (2022) Vol. 36, Iss. 7
Closed Access | Times Cited: 1
Microbiota-associated metabolic reprograming influenced clinical outcome in the randomized dendritic cell-based clinical trial in stage III melanoma
Carolina Alves Costa Silva, Mélanie Bourgin, Gianmarco Piccinno, et al.
Research Square (Research Square) (2023)
Open Access
Do patients receive any benefit from the addition of perioperative immunotherapy-chemotherapy for solid tumors?
Rencui Quan, Zaishang Li, Huaqing Zhang, et al.
Medicine (2023) Vol. 102, Iss. 42, pp. e35603-e35603
Open Access
Immunotherapy-based Combination Therapies for Malignant Melanomas
Pouya Mahdavi Sharif, Nima Rezaei
Interdisciplinary cancer research (2022)
Closed Access
Page 1

Scroll to top